New publication “Diagnosis and treatment of patients with gastroesophageal reflux disease –a systematic review of cost-effectiveness and economic burden”

Another successfull publication for Betthera team! This time, Betthera published systematic review about diagnosis and treatment of patients with gastroesophageal reflux disease.

The systematic review reveals a significant economic burden from GERD, driven by both high direct costs of treatment and diagnostics (especially with traditional invasive methods) and indirect costs related to work absenteeism and reduced productivity. Proton Pump Inhibitors (PPIs) are cost-effective for most patients, but new diagnostic tools and therapies, such as wireless pH capsules and novel acid blockers, are emerging as potentially more efficient yet costly alternatives.

For the eCAP project, these findings underscore the value of a minimally invasive, implantable capsule and e-health platform, which could reduce the need for hospital-based diagnostics and repeated interventions. By enabling remote, real-time GI monitoring through an integrated smartphone and cloud-based system, eCAP has the potential to lower overall GERD management costs and improve access to advanced diagnostics, particularly in low-resource settings.

You can find the fulltext of publication there.